Foghorn Therapeutics Inc Cash Flow-to-Debt Ratio
Foghorn Therapeutics Inc cash flow-to-debt ratio. Foghorn Therapeutics Inc (FHTX) has a Cash Flow-to-Debt Ratio of -0.07x as of June 2026, meaning its operating cash flow of $-18.90 Million could theoretically repay 0% of its total liabilities ($284.43 Million) in one year. See Foghorn Therapeutics Inc (FHTX) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Foghorn Therapeutics Inc (2018–2025)
Cash flow-to-debt ratio of Foghorn Therapeutics Inc from 2018 to 2025. Historical debt coverage capacity for Foghorn Therapeutics Inc across 8 annual periods. Check Foghorn Therapeutics Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Foghorn Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2018–2025)
Foghorn Therapeutics Inc cash flow-to-debt ratio by year from 2018 to 2025. Year-by-year debt coverage analysis for Foghorn Therapeutics Inc. For the full cash flow conversion analysis, see Foghorn Therapeutics Inc (FHTX) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.28x | $-86.10 Million | $306.60 Million | ▲ +7.8% |
| 2024 | -0.30x | $-100.41 Million | $329.51 Million | ▲ +6.3% |
| 2023 | -0.33x | $-118.11 Million | $363.11 Million | ▼ -168.0% |
| 2022 | 0.48x | $193.61 Million | $404.77 Million | ▲ +502.6% |
| 2021 | -0.12x | $-50.25 Million | $422.90 Million | ▲ +58.4% |
| 2020 | -0.29x | $-31.29 Million | $109.41 Million | ▲ +31.9% |
| 2019 | -0.42x | $-46.34 Million | $110.36 Million | ▼ -52.6% |
| 2018 | -0.28x | $-22.65 Million | $82.33 Million | — |